Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape

Glaire MA. et al, (2022), The Journal of Pathology

Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies.

Ryan NAJ. et al, (2021), Cancers, 13

Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer.

Jiang D. et al, (2021), EBioMedicine, 71

Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.

McAlpine JN. et al, (2021), Cancer, 127, 2409 - 2422

Promises and challenges of adoptive T-cell therapies for solid tumours

Morotti M. et al, (2021), British Journal of Cancer, 124, 1759 - 1776

Correction to: The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability.

Russell H. et al, (2021), Clinical epigenetics, 13

The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.

Alexander PG. et al, (2020), Br J Cancer

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer.

Bergsland CH. et al, (2020), ESMO open, 5

PROGNOSTIC INTEGRATED IMAGE-BASED IMMUNE AND MOLECULAR PROFILING IN EARLY-STAGE ENDOMETRIAL CANCER.

Horeweg N. et al, (2020), Cancer immunology research

The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability.

Russell H. et al, (2020), Clinical epigenetics, 12

Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.

Roseweir AK. et al, (2020), The journal of pathology. Clinical research

Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.

León-Castillo A. et al, (2020), The Journal of pathology, 250, 312 - 322

Interpretation of somatic POLE mutations in endometrial carcinoma.

León-Castillo A. et al, (2020), The Journal of pathology, 250, 323 - 335

Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.

Skrede O-J. et al, (2020), Lancet (London, England), 395, 350 - 360

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.

Lau D. et al, (2020), ESMO open, 5

Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage.

Glaire MA. et al, (2019), British journal of cancer, 121

The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.

Crosbie EJ. et al, (2019), Genetics in medicine : official journal of the American College of Medical Genetics, 21, 2390 - 2400

A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer.

Workel HH. et al, (2019), Cancer Immunol Res, 7, 784 - 796

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM. et al, (2019), Clin Cancer Res, 25, 1087 - 1097

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V. et al, (2019), J Natl Cancer Inst

Load More

Include forthcoming?